medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2011, Número 09-10

<< Anterior Siguiente >>

Medicina & Laboratorio 2011; 17 (09-10)


Hepatitis C

Restrepo GJC, Toro MAI

Idioma: Español
Referencias bibliográficas: 89
Paginas: 411-428
Archivo PDF: 1769.71 Kb.


RESUMEN

La hepatitis C es una enfermedad causada por el virus de la hepatitis C y es la principal causa de cirrosis y trasplante hepático en el mundo occidental. Se estima que el 3% de la población mundial está infectada por este virus. La mayoría de las infecciones son asintomáticas y cuando se manifiestan aparecen síntomas inespecíficos como fatiga, náusea, mialgias y fiebre, que pueden hacer difícil el diagnóstico inicial. En la progresión de la enfermedad a la etapa crónica participan factores relacionados con el virus, el hospedero y también algunos factores externos. El hallazgo de unas pruebas de laboratorio anormales o signos de cirrosis debe hacer pensar en una hepatitis C. Para el diagnóstico se dispone de pruebas serológicas y virológicas; las serológicas detectan anticuerpos contra el virus, en tanto que las virológicas detectan el RNA viral. La gran variedad de cuasiespecies y la variabilidad del virus de la hepatitis C no han permitido hasta ahora la síntesis de una vacuna que brinde protección.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Senecal DL, Morelli J. Hepatitis C virus infection: a current review. JAAPA 2007; 20: 21-25.

  2. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008; 103: 1283-1297; quiz 1298.

  3. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol 2007; 13: 2461-2466.

  4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.

  5. Franciscus A. A brief history of hepatitis C. Hcspfactsheet. http://www.hcvadvocate.org. Accesado en septiembre 3 de 2011.

  6. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767-770.

  7. Ferreon JC, Ferreon AC, Li K, Lemon SM. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005; 280: 20483-20492.

  8. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.

  9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.

  10. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-12771.

  11. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999; 73: 1118-1126.

  12. Restrepo JC. Serologías en las hepatitis virales. Iatreia 2011; 24: 76-86.

  13. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80: 6964-6972.

  14. Lemon SM, Walker CM, Alter MJ, Yi M. Hepatitis C virus. In: Knipe DM, Howley PM (eds). Fields Virology, 5th edition. Philadelphia: Lipincott Williams & Wilkins Pubishers; pp. 1253-1304, 2007.

  15. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.

  16. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.

  17. World Health Organization. Hepatitis C. Global alert and response. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html. Accesado en agosto 30 de 2011.

  18. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006; 44: 455-461.

  19. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235.

  20. Mendez-Sanchez N, Gutierrez-Grobe Y, Kobashi-Margain RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9 Suppl: 27-29.

  21. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.

  22. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441.

  23. Spada E, Mele A, Ciccozzi M, Tosti ME, Bianco E, Szklo A, et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis 2001; 33: 778-784.

  24. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006; 55: 1183-1187.

  25. Soza A, Riquelme A, Arrese M. Routes of transmission of hepatitis C virus. Ann Hepatol 2010; 9 Suppl: 33.

  26. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010; 202: 984-990.

  27. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 7-16.

  28. Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010; 81: 1351-1357.

  29. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S.

  30. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011; 100: 92-98.

  31. Hladik W, Kataaha P, Mermin J, Purdy M, Otekat G, Lackritz E, et al. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health 2006; 11: 951-954.

  32. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180-187.

  33. Hutchinson SJ, Taylor A, Goldberg DJ, Gruer L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention of blood-borne viruses. Addiction 2000; 95: 931-940.

  34. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect 2006; 82 Suppl 3: iii10-17.

  35. Contreras AM, Sotelo M, Celis A, Villalobos DB, Ancona- Piste O, Ochoa-Jimenez RJ, et al. [In Process Citation]. Salud Publica Mex 2011; 53 Suppl 1: S19-25.

  36. Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005; 41: 1423-1430.

  37. Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis 2008; 14: 10-14.

  38. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398, vi.

  39. Heller T, Seeff LB. Viral load as a predictor of progression of chronic hepatitis C? Hepatology 2005; 42: 1261-1263.

  40. Irving WL. Acute hepatitis C virus infection: a neglected disease? Gut 2006; 55: 1075-1077.

  41. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol 2010; 9 Suppl: 8-26.

  42. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int 2009; 29 Suppl 1: 89-99.

  43. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.

  44. Restrepo JC. Hepatitis virales. In: Vélez H, Rojas W, Borrero J, Restrepo J, editors. Fundamentos de Medicina. Enfermedades infecciosas. Editorial Corporación para Investigaciones Biológicas CIB. Sexta edición; 2003. p. 169-174.

  45. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C--natural history and cofactors. Aliment Pharmacol Ther 2005; 22 Suppl 2: 74-78.

  46. George E, Nadkarni GN, Estrella MM, Lucas GM, Sperati CJ, Atta MG, et al. The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immunodeficiency Virus (HIV): A Biopsy Study. Medicine (Baltimore) 2011; 90: 289-295.

  47. Sterling RK, Sulkowski MS. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 2004; 24 Suppl 2: 61-68.

  48. Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999; 45: 613-617.

  49. Hepatitis Foundation International. http://www.hepfi.org. Accesado el 10 de agosto de 2011.

  50. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-327.

  51. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.

  52. Carvajal JJ, Correa G, Restrepo JC. Hepatitis C aguda. Revisión de un caso. Acta Med Colomb 2008; 33: 28-32.

  53. Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med 1993; 86: 119-125.

  54. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.

  55. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-1301.

  56. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.

  57. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.

  58. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356.

  59. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 1997; 112: 463-472.

  60. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316.

  61. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374.

  62. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.

  63. Garcia Ferrera WO, Nodarse Cuni H, Moredo Romo E. [Extrahepatic manifestations of infection with hepatitis C virus]. Rev Gastroenterol Peru 2009; 29: 254-261.

  64. Gadano A, Galdame O, Marciano S. Diagnosis of patients with suspected chronic hepatitis C infection. Ann Hepatol 2010; 9 Suppl: 34-38.

  65. O’Leary JG, Davis GL. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ (eds). Feldman: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 9th ed. Philadelphia: Saunders, an imprint of Elsevier; pp. 1313-1331, 2010.

  66. Asociación Española para el Estudio del Hígado, Asociación Española de Gastroenterología, Asociación Latinoamericana para el Estudio del Hígado, Asociación Interamericana de Gastroenterología. Consenso para el tratamiento de las hepatitis B y C. Gastroenterol Hepatol 2006; 29: 1-241.

  67. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.

  68. Moradpour D, Cerny A, Heim MH, Blum HE. Hepatitis C: an update. Swiss Med Wkly 2001; 131: 291-298.

  69. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169-176; x.

  70. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  71. Idrovo V. Asociación Colombiana de Hepatología. http://www.higadocolombia.org/index.php?option=com_content&view=article&id=45:aproximacionterapeuticaa-la-hepatitis-por-virus-c. Accesado en octubre 14 de 2011.

  72. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S. Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A populationbased cohort study (JPHC Study). Cancer Lett 2011; 300: 173-179.

  73. Michaels AJ, Nelson DR. New therapies in the management of hepatitis C virus. Curr Opin Gastroenterol 2010; 26: 196-201.

  74. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48: 313-320.

  75. Murray KF, Shah U, Mohan N, Heller S, Gonzalez-Peralta RP, Kelly D, et al. Chronic hepatitis. J Pediatr Gastroenterol Nutr 2008; 47: 225-233.

  76. Castañeda R, Muñoz LE. Hepatitis víricas agudas. In: Muñoz LE, ed. Hepatología, 1a ed. México, DF: Mc- Graw Hill; pp. 75-89, 2007.

  77. De la Vega A, Frauca E. Conducta ante la hepatitis por el VHC. In: Jara P, Coordinadora. Protocolos diagnósticos y terapéuticos en Pediatría, tomo 5: Gastroenterología, Hepatología, Nutrición. Asociación Española de Pediatría; 2002: 203-211.

  78. Loomba R, Rivera MM, McBurney R, Park Y, Haynes- Williams V, Rehermann B, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559-565.

  79. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1-113, iii.

  80. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-1338.

  81. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010; 17: 34-50.

  82. Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opin Investig Drugs 2010; 19: 63-75.

  83. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.

  84. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.

  85. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.

  86. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.

  87. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.

  88. Ray K. Viral hepatitis: Promising phase I trial results for TG4040 vaccine in patients with chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 420.

  89. Warley E, Desse J, Szyld E, Silva FN, Cetani S, Pereyra N, et al. [Occupational exposure to hepatitis C virus]. Medicina (B Aires) 2006; 66: 97-100.




2020     |     www.medigraphic.com